Early-stage funding for European life sciences companies

We are a venture capital firm specialised in seed investment for innovative early stage companies. BGV generally acts as lead investor. Our current portfolio comprises of biotech developing truly disruptive solutions for high unmet medical needs.

Acerta, a multi-billion Euro success story

BioGeneration was co-founder and investor in the most successful biotech startup in Europe: Acerta Pharma. Acerta Pharma has developed Calquence® (acalabrutinib), a drug now approved by the FDA for the treatment of hematologic malignancies (leukemia). Acerta was sold to AstraZeneca for up to US$ 7 billion in 2016.

Shaping new life-science ventures

We gained our experience from working within small and large pharma and biotech companies. Based on this experience and through our extensive industry network, we are able to bring a range of sector-relevant expertise to help accelerate product development and shape the companies to become attractive investment opportunities for the industry.

Latest news

VarmX raises €32 million in Series B financing to develop innovative reversal agent for the treatment and prevention of severe bleeding in patients on oral anticoagulants

Jul 8, 2020

Financing co-led by Ysios Capital and INKEF Capital, joined by Lundbeckfonden Ventures, LSP, and existing investors BioGeneration Ventures and InnovationQuarterProceeds to be used to achieve clinical proof of concept for lead compound, VMX-C001, advance program to...

Citryll completes € 18.5 M fundraise to develop CIT-013, an antibody targeting Neutrophil Extracellular Traps

Jul 2, 2020

Oss, The Netherlands, July 2, 2020 —Citryll announced it closed a total fundraise of € 18.5 million, led by Seventure(including their Health for Life Capital II fund), co-led by BioGeneration Ventures (BGV) with existing investors BOMBrabant Ventures, BrightGene and...

Scenic Biotech Appoints Oscar Izeboud as Chief Executive Officer

Jul 1, 2020

Amsterdam, The Netherlands, 1 July 2020 - Scenic Biotech BV (“Scenic”), a pioneer in the discovery of genetic modifiers to enable the development of disease modifying therapeutics for rare genetic disorders and other devastating illnesses, today announced that Dr C....

BioGeneration Ventures closes BGV IV fund at €105 million

Jun 24, 2020

Investors include Bristol Myers Squibb, European Investment Fund, Industriens Pension, KfW Capital, Schroder Adveq Investment focus on entrepreneurial innovation in therapeutics in Europe Total assets under management >€220 million ($250m) Naarden, The...

News overview